When we analyzed KRAS and GNAS DNA mutational profiles in our cohort, we found that the proportion of KRAS mutations was significantly higher in the PanIN-derived group, and GNAS mutations were significantly more common in the IPMN-derived group (Figure S2). This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.